KOL panel to discuss how vispa-cel, an anti-CD19 allogeneic CAR-T cell therapy, can broaden access for patients with second-line large B cell ...

Researchers release a comprehensive viral genome database covering diverse ecosystems to advance understanding of viral ...

Title: CRISPR/Cas-mediated APOC3 Knockout as a One-time Treatment for Severe Hypertriglyceridemia Presenters: Alan Brooks, PhD, Senior Vice President of Research at Metagenomi Date/time: Monday, ...

As of November 27, CRISPR Therapeutics AG (NASDAQ:CRSP) has a moderately positive opinion, with 60% analysts covering it having a Buy or equivalent rating. With a consensus 1-year median price target ...

This year has seen the approval of several first-in-class therapies for HAE, but in a fragmented space, experts question ...

The convergence of genomics, systems biology, and artificial intelligence is transforming the landscape of drug discovery. Modern genomic technologies now ...

But sometimes, this top investor who focuses on innovation does see eye-to-eye with analysts, and the perfect example of this ...

It might be time to look a bit off the beaten path, at names that can stand up to any AI-stock-led correction.

Following the weekend data presentation, Citizens voiced optimism regarding CRISPR’s in-vivo projects. The firm noted some ...

Highlighting 10 innovative late-stage BioPharma drugs with the potential to reshape treatment paradigms and industry dynamics ...

The immune system plays a crucial role in fighting tumors and metastases. Consequently, it is decisive to conduct cancer ...